BHVNBiohaven Ltd.

1. Sep 10, 2026Biohaven Ltd. (the “Company,” “we” or “our”) is providing updates to the BHV-7000 program. We refer you to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for a description of the BHV-7000 program.Other event · Form 8-K
2. Aug 26, 2026License Agreement On August 26, 2026, Biohaven Bioscience Ireland Limited (“BBIL”), a wholly owned subsidiary of Biohaven Ltd. (the “Company”), entered into a License Agreement (the “License Agreement”) with SK Biopharmaceuticals Co., Ltd. (“SKBP”)Material agreement entered · Form 8-K
3. Aug 10, 2026Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results.Earnings release · press release
4. Aug 7, 2026On August 3, 2026, the Board of Directors (the “Board”) of Biohaven Ltd. (the “Company”) appointed John Yetimoglu as a director, effective August 6, 2026.Director or officer change · Form 8-K
5. Jul 9, 2026On July 9, 2026, Biohaven Ltd. (the “Company”) and Bruce Car, Ph.D., mutually agreed that, effective July 13, 2026, Dr. Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer.Director or officer change · Form 8-K
6. May 27, 2026Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile.Regulation FD disclosure · press release
7. May 5, 2026On May 4, 2026, Biohaven Ltd. (the “Company”) entered into Amendment No. 2 (“Amendment No. 2”) to the Equity Distribution Agreement, dated October 2, 2023 (the “Original Equity Distribution Agreement”), as previously amended by Amendment No. 1, dated August 16, 2024 (“Amendment No. 1” and, together with the Original …Other event · Form 8-K
8. May 4, 2026Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results.Earnings release · press release
9. Mar 2, 2026Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
10. Jan 7, 2026On January 6, 2026, Biohaven Ltd. (the “Company”) agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at a purchase price of $10.00 per share.Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.